• Cancel
    Date:2019-04
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=419

    Tencent Trusted Doctor Group (hereinafter referred to as “Tencent Trusted Doctor”), the largest non-public medical service platform in China, has raised $250 million in its most recent fundraising round. This round of financing was jointly led by Country Garden Holdings, Tencent, and GAW Capital. Follow investors included CMB International, Harvest Wealth, Russia-China Investment Fund, Sequoia China, SenseGain, and AVIC Trust. This was the first round of investment since the merger between Tencent Doctorwork and Trusted Doctors in 2018. CEC Capital acted as the sole financial adviser to Tencent Trusted Doctor for this round of financing.

  • Cancel
    Date:2019-02
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=413

    China’s leading therapeutic antibody R&D company, SinoMab Bioscience Limited (“SinoMab”) just completed a Pre-IPO round of financing, securing some hundreds of millions in RMB. This round of investment was co-led by Zhongjin Zhide Equity Investment Management (an investment arm of China International Capital Corporation Limited) and Apricot Capital. SinoMab also announced that it will begin work on its IPO. CEC Capital served as the sole financial adviser to SinoMab during this round of financing.

  • Cancel
    Date:2019-01
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=411

    Taicang, Suzhou, January 2, 2019/PRNewswire / - Connect Biopharmaceuticals, a clinical-stage company that discovers and develops novel immune modulators for the treatment of autoimmune diseases and inflammation, today announces the completion of a $55 mil

  • Cancel
    Date:2018-12
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=412

    In December 2018, Shanghai Cell Therapy Group Co., Ltd. (the “Company”), a leader in China’s cell therapy medical industry, announced the completion of its C round of financing, raising RMB 925 million (US$134M). The financing was co-led by China Pacific Insurance, Haier Capital, and China Industrial Asset Management Limited, with participation from existing investors Legend Capital, Anting People's Government, and Ningbo Yuanhui. The Company used this round of financing to bring on-board strategic investors that can provide significant business synergies across the various parts of its business. The capital will be used for R&D of innovative cellular technologies and treatments, development of cryopreservation technologies, and the construction of high-end cancer hospitals. CEC Capital served as the exclusive financial adviser for this round of financing.

  • Cancel
    Date:2018-11
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=404

    On November 7, 2018, in Beijing, AI medical imaging leader, HuiyiHuiying, announced that it received investments from Intel Capital and Beijing Kinetic Energy Investment Fund, completing a strategic round of investment. The funds will be used for the comp

  • Cancel
    Date:2018-06
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=406

    Pioneer of the 3D printed pharmaceutical industry, Nanjing Triastek Pharmaceutical Technology Co., Ltd. (also known as “Triastek”), recently raised RMB 100 million, completing its A round of financing. The lead investor was Morningside Venture Capital and the follow investors were Volcanics Ventures and InnoVision Capital. CEC Capital served as the sole financial adviser to CMLabs during this round of financing.

  • Cancel
    Date:2018-05
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=405

    Leading third-party medical testing service provider, Chain Medical Labs (CMLabs), recently announced that it raised hundreds of millions of RMB and the completed its latest B round of financing. The co-lead investors were C-Bridge Capital and Huatai Ruih

  • Cancel
    Date:2018-04
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=369

    Innovative Cellular Therapeutics (ICT) announced that the company had completed its Series B financing of RMB 180 million. Investors in this new round included Volcanics Venture, GTJA Investment Group, SBCVC, Dunhou Capital and Withtruth Capital. The com

  • Cancel
    Date:2018-03
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=352

    EYEGOOD OPHTHALMIC, chain brand of domestic leading ophthalmic hospital, announced that the company has completed $40 million series B financing led by CDH Investments. This is a new round of financing after series A by OrbiMed in 2015.